Qmiiz Odt is a drug owned by Tersera Therapeutics Llc. It is protected by 1 US drug patent filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 31, 2030. Details of Qmiiz Odt's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8545879 | Fast disintegrating compositions of meloxicam |
Aug, 2030
(5 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Qmiiz Odt's patents.
Latest Legal Activities on Qmiiz Odt's Patents
Given below is the list of recent legal activities going on the following patents of Qmiiz Odt.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Mar, 2021 | US8545879 |
| Mail Pre-Exam Notice | 25 May, 2017 | US8545879 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Oct, 2013 | US8545879 |
| Recordation of Patent Grant Mailed Critical | 01 Oct, 2013 | US8545879 |
| Issue Notification Mailed Critical | 11 Sep, 2013 | US8545879 |
| Dispatch to FDC | 03 Sep, 2013 | US8545879 |
| Application Is Considered Ready for Issue Critical | 03 Sep, 2013 | US8545879 |
| Issue Fee Payment Received Critical | 29 Aug, 2013 | US8545879 |
| Issue Fee Payment Verified Critical | 29 Aug, 2013 | US8545879 |
| Mail Applicant Initiated Interview Summary | 31 May, 2013 | US8545879 |
US patents provide insights into the exclusivity only within the United States, but Qmiiz Odt is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Qmiiz Odt's family patents as well as insights into ongoing legal events on those patents.
Qmiiz Odt's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Qmiiz Odt's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 31, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Qmiiz Odt Generic API suppliers:
Meloxicam is the generic name for the brand Qmiiz Odt. 25 different companies have already filed for the generic of Qmiiz Odt, with Aiping Pharm Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Qmiiz Odt's generic
Alternative Brands for Qmiiz Odt
There are several other brand drugs using the same active ingredient (Meloxicam) as Qmiiz Odt. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Avondale Pharms |
| |
| Baudax |
| |
| Heron Theraps Inc |
| |
| Iceutica Operations |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Meloxicam, Qmiiz Odt's active ingredient. Check the complete list of approved generic manufacturers for Qmiiz Odt
About Qmiiz Odt
Qmiiz Odt is a drug owned by Tersera Therapeutics Llc. Qmiiz Odt uses Meloxicam as an active ingredient. Qmiiz Odt was launched by Tersera in 2018.
Approval Date:
Qmiiz Odt was approved by FDA for market use on 19 October, 2018.
Active Ingredient:
Qmiiz Odt uses Meloxicam as the active ingredient. Check out other Drugs and Companies using Meloxicam ingredient
Dosage:
Qmiiz Odt is available in tablet, orally disintegrating form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |
| 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |